iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
The Lancet Oncology.
Times cited: 319
Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab.
Journal of Clinical Oncology.
Times cited: 294
Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer.
Times cited: 59